Effect of SMAD7 gene overexpression on TGF-β1-induced profibrotic responses in fibroblasts derived from Peyronie's plaque

Asian Journal of Andrology

Volumn 17, Issue 3, 2015, Pages 487-492

  Choi, Min ^a   Song, Kang Moon ^a   Park, Jin Mi ^a   Kwon, Mi Hye ^a   Kwon, Ki Dong ^a   Park, Soo Hwan ^a   Ryu, Dong Soo ^b   Ryu, Ji Kan ^a   Suh, Jun Kyu ^a  

^a Inha University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

cell culture; decapentaplegic homolog 7; fibrosis; Peyronie's disease; transforming growth factor beta

Indexed keywords

CYCLIN D1; HYDROXYPROLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SCLEROPROTEIN; SMAD7 PROTEIN, HUMAN;

ARTICLE; CELL TRANSDIFFERENTIATION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; MYOFIBROBLAST; PEYRONIE DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUNEL ASSAY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; FIBROSIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PENILE INDURATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

CELLS, CULTURED; CYCLIN D1; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBROSIS; HUMANS; HYDROXYPROLINE; MALE; PENILE INDURATION; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84928988075     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.142130     Document Type: Article

References (37)

1. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int 2001; 88: 727-30
2. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171: 2350-3
3. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997; 158: 1388-90
4. Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997; 157: 285-90
5. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006; 49: 987-97
6. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, et al. Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol 2006; 50: 235-48
7. Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 2012; 187: 2268-74
8. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013; 190: 199-207
9. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394-8
10. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010; 106: 240-8
11. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 63-7
12. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522-4
13. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009; 41: 467-71
14. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, et al. Gene expression in Peyronie's disease. Int J Impot Res 2002; 14: 361-74
15. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4
16. Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007; 51: 255-61
17. Piao S, Choi MJ, Tumurbaatar M, Kim WJ, Jin HR, et al. Transforming growth factor (TGF)-s type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-s1 responses in fibroblasts derived from Peyronie's plaque. J Sex Med 2010; 7: 3385-95
18. Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009; 6: 1284-96
19. Ryu JK, Kim WJ, Choi MJ, Park JM, Song KM, et al. Inhibition of histone deacetylase 2 mitigates profibrotic TGF-s1 responses in fibroblasts derived from Peyronie's plaque. Asian J Androl 2013; 15: 640-5
20. Lin G, Shindel AW, Banie L, Ning H, Huang YC, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010; 7: 1787-97
21. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-5
22. Lebrun JJ, Takabe K, Chen Y, Vale W. Roles of pathway-specific and inhibitory Smads in activin receptor signaling. Mol Endocrinol 1999; 13: 15-23
23. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365-75
24. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A 2004; 101: 8687-92
25. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104: 5-11
26. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-59
27. Song KM, Chung JS, Choi MJ, Jin HR, Yin GN, et al. Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury. J Sex Med 2014; 11: 51-63
28. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-9
29. Hamzavi J, Ehnert S, Godoy P, Ciuclan L, Weng H, et al. Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med 2008; 12: 2130-44
30. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-9
31. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178-91
32. Bian EB, Huang C, Wang H, Chen XX, Zhang L, et al. Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats. Toxicol Lett 2014; 224: 175-85
33. Hou CC, Wang W, Huang XR, Fu P, Chen TH, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005; 166: 761-71
34. Okado T, Terada Y, Tanaka H, Inoshita S, Nakao A, et al. Smad7 mediates transforming growth factor-beta-induced apoptosis in mesangial cells. Kidney Int 2002; 62: 1178-86
35. Hong S, Kim HY, Kim J, Ha HT, Kim YM, et al. Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J Biol Chem 2013; 288: 3560-70
36. Kim MY, Zhang T, Kraus WL. Poly (ADP-ribosyl) ation by PARP-1: 'PAR-laying' NAD+into a nuclear signal. Genes Dev 2005; 19: 1951-67
37. Lonn P, van der Heide LP, Dahl M, Hellman U, Heldin CH, et al. PARP-1 attenuates Smad-mediated transcription. Mol Cell 2010; 40: 521-32